Virogenics, Inc.

Virogenics, Inc. is a for-profit biotechnology company located in San Diego, California, focused on developing innovative therapeutic approaches for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease (AD) drug development. The company appears to specialize in pharmaceutical research and development, specifically targeting novel drug candidates that address complex neurological conditions through unique mechanisms of action. Through federal grant awards, Virogenics, Inc. primarily engages with the National Institute on Aging (NIA) to advance cutting-edge medical research and develop potential breakthrough treatments for age-related cognitive disorders.

The company has been actively pursuing the development of CMS121, a small molecule drug candidate designed to treat Alzheimer's disease, through a series of federally funded research grants. These grants, totaling over $5.6 million, have supported critical research stages including a first-in-human Phase 1 clinical trial, long-term non-clinical toxicology studies, and preparatory work for potential Phase 2 clinical trials. The research focuses on developing a disease-modifying drug that addresses cognitive impairment by targeting lipid metabolism and mitochondrial function, which differs from existing Alzheimer's treatments. The grants have funded specific activities such as 6-month rat and 9-month dog toxicology studies, development of a tablet formulation of CMS121, and comprehensive clinical trial protocols, all aimed at advancing a novel therapeutic approach for treating mild to moderate Alzheimer's disease. Collaborating with scientific partners like the Salk Institute, Virogenics, Inc. has leveraged these federal awards to progress its innovative drug development research through rigorous scientific investigation and clinical testing.